化合物RX-3117 T16813

Product Introduction
Bioactivity


英文名: RX-3117

描述: RX-3117 (fluorocyclopentenylcytosine) 是一种新型的胞苷类似物，在几种癌细胞系中显示出抗癌活性，包括对吉西他滨耐药的变体。

体外活性: RX-3117 was a very poor substrate for cytidine deaminase (66,000-fold less than gemcitabine). RX-3117 showed a different sensitivity profile compared to cyclopentenyl-cytosine and azacytidine, substrates for uridine-cytidine-kinase. Insensitive U937 cells 1 μM RX-3117 resulted in 90% inhibition of RNA synthesis but 100 μM RX-3117 was required in A2780 and CCRF-CEM cells. RX-3117 at IC50 values did not affect the integrity of RNA [1].

体内活性: RX-3117 (p.o.) was examined in 9 different human tumor xenograft models grown subcutaneously in athymic nude mice. In the Colo 205, H460, H69 and CaSki models, gemcitabine treatment resulted in 28%, 30%, 25% and 0% tumor growth inhibition (TGI), respectively. Whereas oral treatment with RX-3117 induced 100%, 78%, 62% and 66% TGI, respectively [2].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 50 mg/mL (194.39 mM)


关键字: Nucleoside Antimetabolite/Analog | S phase | DNMT1 | inhibit | orally active | RX 3117 | apoptosis | RX3117 | antiproliferative | RX-3117 | TV 1360 | Inhibitor | TV1360 | anti-tumour

相关产品: ddUTP (lithium), 100mM in H2O | Enocitabine | Clofarabine | Carmofur | 2′-C-Methyl-6-O-methylinosine | N6-Methyladenine | Homouridine | Trifluridine | Sangivamycin | 2',5-Difluoro-2'-deoxy-1-arabinosyluracil

相关库: Drug Repurposing Compound Library | Cell Cycle Compound Library | Anti-Cancer Drug Library | Bioactive Compounds Library Max | Anti-Cancer Clinical Compound Library | Anti-Cancer Active Compound Library | Orally Active Compound Library | Reprogramming Compound Library | Bioactive Compound Library | Anti-Infection Compound Library

化合物RX-3117 T16813信息由TargetMol中国为您提供，如您想了解更多关于化合物RX-3117 T16813报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途